Intravenous (IV) Iron Drugs 2018: Global Strategic Business

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
Intravenous (IV) Iron Drugs 2018: Global Strategic Business Outlook to 2024 - Expanding Pool of ESRD and CKD Patients: The Major Growth Driver

Dublin, July 03, 2018 (GLOBE NEWSWIRE) -- The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand. The report profiles 21 companies including many key and niche players such as:

  • Allergan Plc. (Ireland)
  • AMAG Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo, Inc. (USA)
  • Luitpold Pharmaceuticals, Inc. (USA)
  • American Regent, Inc. (USA)
  • Pharmacosmos A/S (Denmark)
  • Sanofi US (USA)
  • Vifor Pharma Ltd. (Switzerland)
  • Vifor Fresenius Medical Care Renal Pharma (Switzerland)

Key Topics Covered

1. GLOBAL MARKET OVERVIEW Iron Deficiency Anemia (IDA) An Overview Intravenous (IV) Iron Drugs Market A Quick Primer US and Europe Dominate IV Iron Market Asia-Pacific The Fastest Growing Market Leading Intravenous Iron Drugs Globally Leading IV Iron Drugs Available in the Market Leading Intravenous Iron Drugs: In a Nutshell Ferinject/Injectafer The Leading Intravenous Iron Drug Globally Venofer® Looses Ground to Ferinject Feraheme Obtains Broader Label Approval Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA Gluconate (Ferrlecit® and Nulecit) Dextran Global Market Leaders 2. GROWTH DRIVERS & MARKET TRENDS Expanding Pool of ESRD and CKD Patients The Major Growth Driver for Intravenous (IV) Iron Drugs ESRD Prevalence Statistics: An Opportunity Indicator Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market Dialysis Patients A Major Market for Intravenous Iron Supplements Ageing Population Drives Demand for IV Iron Drugs Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs Comparison of Ferrous Salts with IV Iron Therapy Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs Anemia in Heart Failure A Market with Huge Potential Chemotherapy Induced Anemia to Promote IV Iron Supplements Correction of IDA in Pregnancy Signals Opportunities Women’s Health A Key Growth Opportunity Perioperative and Postoperative Anemia A Niche Market Beckons Adverse Reactions of IV Iron Preparations Raise Concerns Dosing Limitations Plague IV Iron Market Select Therapeutic Areas and the Required Iron Doses 3. REGULATORY OVERVIEW Increasing Trend towards Bundled Reimbursements A Glimpse of Regulations in the US and Europe Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. RECENT INDUSTRY ACTIVITY AMAG to Expand Feraheme® Label Pharmacosmos and Laboratoire Aguettant to Commercialize Monover® in France Pharmacosmos and Pfizer to Commercialize Monover® in Brazil Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV) Administration Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer® in Japan Lupin Announces the Launch of Novel Injectable Iron Formulation in India Pharmacosmos and Pfizer to Commercialize Monofer® in Canada 6. FOCUS ON SELECT PLAYERS Allergan Plc. (Ireland) AMAG Pharmaceuticals, Inc. (USA) Daiichi Sankyo, Inc. (USA) Luitpold Pharmaceuticals, Inc. (USA) American Regent, Inc. (USA) Pharmacosmos A/S (Denmark) Sanofi US (USA) Vifor Pharma Ltd. (Switzerland) Vifor Fresenius Medical Care Renal Pharma (Switzerland) 7. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 21 (including Divisions/Subsidiaries 22) The United States ((5) Japan (2) Europe (7) - France (1) - Germany (1) - The United Kingdom (1) - Rest of Europe (4) Asia-Pacific (Excluding Japan) (8)

For more information about this report visit https://www.researchandmarkets.com/research/b...us_iv?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infusions and Injectables , Hematological Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

SRM Entertainment Expands Horizon with Strategic Moves.

Updated Category News Views 238

SRM Entertainment's Strategic Growth Plans SRM Entertainment, Inc. (Nasdaq: SRM) is taking bold steps to enhance its market position and create long-term value for its shareholders. Despite receiving numerous inquiries from investors regarding potential capital raises, the company has confirmed no immediate plans to seek additional funding. This strategic decision aligns...

Continue Reading
SBA Communications Unveils Tax Reporting Details for 2024

Updated Category News Views 149

SBA Communications Corporation Announces 2024 Tax Reporting Insights SBA Communications Corporation (Nasdaq: SBAC) has shared important tax reporting information concerning its distributions for 2024. As stockholders prepare for their tax obligations, the company encourages them to seek advice from their personal tax advisors to ensure they understand their specific tax...

Continue Reading
electroCore Achieves Significant Milestone with New Patents

Updated Category News Views 157

electroCore Enhances Innovation Through New Patents electroCore, Inc. (NASDAQ: ECOR), a leading figure in the bioelectronic medicine and wellness space, has recently made headlines by receiving notifications for five new patents issued by the United States Patent and Trademark Office (USPTO). This expansion of its intellectual property portfolio not only underscores...

Continue Reading
Empowering Grassroots: A Great Idea’s New Microgrant Initiative

Updated Category News Views 252

Introducing the A Great Idealist Microgrant Program A Great Idea (AGI) has recently unveiled its A Great Idealist Microgrants program, designed to provide crucial financial support to grassroots organizers, community advocates, and innovative leaders across the nation. This initiative echoes AGI's commitment to uplift and empower those at the forefront of social change....

Continue Reading
Elevat and HydraForce Team Up for Game-Changing Solutions

Updated Category News Views 249

Dynamic Partnership Set to Transform OEM Offerings What’s brewing in the world of industrial machine intelligence? It’s more than a merger—it’s a strategic collaboration that’s about to shake things up. Elevat, that Seattle-based powerhouse known for its cutting-edge solutions, has joined forces with HydraForce, backed by Bosch, to roll out some impressive...

Continue Reading